SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare zooms as its finished dosage formulation facility gets GMP certification from Russian Federation

31 May 2021 Evaluate

Shilpa Medicare is currently trading at Rs. 531.00, up by 14.75 points or 4.21% from its previous closing of Rs. 516.25 on the BSE.

The scrip opened at Rs. 519.00 and has touched a high and low of Rs. 543.10 and Rs. 510.00 respectively. So far 54211 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 692.45 on 11-Aug-2020 and a 52 week low of Rs. 317.05 on 19-Mar-2021.

Last one week high and low of the scrip stood at Rs. 546.90 and Rs. 510.00 respectively. The current market cap of the company is Rs. 4386.15 crore.

The promoters holding in the company stood at 53.25%, while Institutions and Non-Institutions held 20.64% and 26.12% respectively.

Shilpa Medicare’s finished dosage formulation facility (Sterile and Non-sterile) located at S-20 to S-26, Pharmaceutical Formulations SEZ, TSIIC, Jadcherla, Telangana State, India has been issued GMP certification by the Ministry of Industry and Trade of the Russian Federation for the GMP inspection held from February 22, 2021 to February 26, 2021. There were No Critical, Major and Minor observations found during GMP inspection process. The GMP certificate is valid for three years until April 2024.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

422.50 10.95 (2.66%)
20-Apr-2026 10:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.75
Dr. Reddys Lab 1235.00
Cipla 1233.60
Zydus Lifesciences 937.25
Lupin 2328.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×